Found the Brilacidin "no problem" info. Right in plain sight on the cellceutix.com website. By the way, remember that Dynabolic stickie-noted the index of CTIX press releases -- it's real easy to scan through that to find the one you're looking for.

This is from the response to the libelous, dead wrong Seeking Alpha article:
http://cellceutix.com/cellceutix-provides-ins...TsolQ.dpbs

Quote:

---

Cellceutix: NOT TRUE. “Antimicrobial peptide resistance” (to native AMPs, such as defensin) is a theoretical problem. It is different from “antibiotic resistance”, which is a growing public health concern.

Brilacidin, a small molecule, can theoretically remain functional in the face of “AMP resistance”, as it is similar, but not identical to, its large molecule counterpart (native AMP). More importantly, it can remain functional in the face of existing “antibiotic resistance”. This is because it is from a brand new class of antibiotics to which resistance has not yet occurred. Therefore, it can be used to treat bacteria that are currently resistant to other antibiotics. In addition, given brilacidin’s mechanism of action, among other properties, the development of specific brilacidin resistance is very unlikely.
- See more at: http://cellceutix.com/cellceutix-provides-ins...TsolQ.dpuf

---

(Brilacidin disrupts the cell wall -- that's the mechanism of action they refer to)